Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…Retrospective exploration of the 5-2-1 criteria in clinical practice
Objective: To explore documentation in medical records (EMRs) of the 5 (5 oral levodopa doses taken/day) -2 (2hours of OFF time/day) -1 (1 hour of…Sex differences for off episodes in Parkinson’s disease
Objective: To determine the sex differences for the frequency, duration, and impact of off episodes in Parkinson’s disease (PD). Background: Dopamine replacement therapy through oral…Continuous algorithmic insights into PD motor symptoms and individual treatment response
Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…Safinamide in Parkinson´s Disease. A retrospective study
Objective: To evaluate the safety of safinamide in Parkinson´s Disease (PD) and determine consequences of direct switch from rasagiline. Background: A wash-out period is recommended…Analysis of a wearable sensor, STAT-on®, to detect motor complications in patients with Parkinson´s disease (PDp)
Objective: Analysis of the use of a personalized monitoring device, STAT-on®, to detect motor complications in PDp and its impact on the therapeutic approach. Background:…Response to Levodopa in Parkinson´s Disease Over Time. A 4-year Follow-up Study.
Objective: The aim of the present study was to analyze the response to levodopa in Parkinson´s disease (PD) patients with motor fluctuations followed up for…Reliability of Indonesian Version Wearing Off Questionnaire
Objective: This study measure the reliability of Indonesia version wearing off (WO) questionnaire for PD patients. Background: The wearing off phenomenon is disabling complication of…Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease
Objective: To investigate the impact of non-motor fluctuations for QOL in patients with Parkinson's disease (PwPD) using a nine-item wearing-off questionnaire (WOQ-9). Background: Long-term levodopa…Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study
Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 24
- Next Page »